Roche enters into exclusive license agreement with Galenica for the commercialisation of Mircera in the United States

Roche announced today that it has entered into an exclusive licence agreement with Galenica for the commercialisation of Roche's drug Mircera (methoxy polyethylene glycol-epoetin beta) in the US and Puerto Rico. Mircera is a prescription medicine used to treat symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients and represents an ideal complement to the existing product portfolio of Galenica for patients with CKD and iron deficiency.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news